According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A look at market access over the past two quarters shows that the percentage of commercial restricted lives increased, while access in other channels stayed relatively flat.
Source: MMIT data as of Q4 2016
Trends: Recent news highlights some key trends in the dermatology-acne landscape. Big data makes its first major debut in the space as highlighted by a recent article from Bloomberg. OptumRx increased the amount of restrictions (specifically, the nature of step therapies for branded acne treatments) after seeing a spike in acne spend under their UnitedHealth plans. Additionally, branded dermatological brands face a high degree of generic competition.
To read the full Reality Check on Dermatology with key findings on clinical characteristics, acne drug market access and payer coverage, please click on the button below: